PPARG and hypertriglyceridemia: Notably, patients with FPLD3 (associated with PPARG pathogenic variants) exhibited a milder lipodystrophy phenotype but a higher prevalence of metabolic complications, such as hypertriglyceridemia and diabetes, emphasizing the clinical heterogeneity within FPLD (1–3).